# A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

> **NCT06165250** · PHASE3 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 156 (actual)

## Conditions studied

- Essential Hypertension
- Primary Hypercholesterolemia

## Interventions

- **DRUG:** BR1018A
- **DRUG:** BR1018A-1
- **DRUG:** BR1018B
- **DRUG:** BR1018B-1
- **DRUG:** BR1018C
- **DRUG:** BR1018C-1

## Key facts

- **NCT ID:** NCT06165250
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-17
- **Primary completion:** 2025-11-11
- **Final completion:** 2025-11-11
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06165250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06165250, "A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06165250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*